SEC Filing Summary: Ocuphire Pharma, Inc. (OCUP)
Business Context and Reporting Period
This Form 8-K was filed by Ocuphire Pharma, Inc. on May 7, 2021. The report serves to announce the company's financial results for the quarter ended March 31, 2021. The registrant is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol OCUP.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notification that these results were issued in a press release (Exhibit 99.1) but does not contain the financial data itself within the body of the 8-K.
Material Changes
No material changes versus the prior comparable period are detailed in this filing text. The document references the issuance of a press release containing the results but does not summarize the specific variances or trends.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, risk factors, or details on contingencies. It explicitly states that the information in Item 2.02 and the attached press release is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liability of that section.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 7, 2021) for actual financial figures and operational updates.
- Verify the specific revenue and net loss figures for the quarter ended March 31, 2021, as they are not listed in this summary document.
- Check for any updated cash runway or liquidity positions mentioned in the referenced press release.
- Confirm if the company has provided any updated clinical trial timelines or regulatory milestones in the full press release.